A group of consumer, senior, patient safety organizations and small insurers, including Community Catalyst and various state public interest research groups, filed their own comments with the FDA o
A group of consumer, senior, patient safety organizations and small insurers, including Community Catalyst and various state public interest research groups, filed their own comments with the FDA on fair balance. Will pharma listen ?
Consumers want to have their own say in fair balance on prescription drug ads. Among their recommendations ;
This is exactly what I have been hearing in two years of qual and quant research and I believe that these requests are reasonable. One other requirement that I believe is necessary is that drug websites have a "roll-over" definition pop-up for complicated medical terms so that consumers can understand label language. It seems that most drug companies do not want to hire writers to take complicated medical language and turn it into easy to understand language that consumers can actually understand and the FDA issues a letter recently to a company that "simplified" it's label language.
PhRMA should be acting as a bridge between consumer groups and pharma marketers to start down the road to earning trust and doing what consumers want and need not doing what is just best for marketers.
Kevin Appareti, global director for Medical Science Liaison at Philips Healthcare, explains how to motivate KOLs and how to measure their value
The Mobile Health Competition is now closed, but the journey is just beginning for the winning idea.
Phil Taylor reports on the commercial and scientific opportunities facing medical scientific liaisons (MSLs)
Alex Gochtovtt, principal with Cognizant’s enterprise analytics practice, discusses pharma’s social media opportunities and the importance of data analytics
An interview with Serkan Erkovan of Boehringer Ingelheim.
Ashok Bhaseen, Vice President of Sales & Marketing at Pediapharm reveals how his company establishes trust when engaging KOLs